In Part I of this three-part series, we focused on three mRNA technology market players: BioNTech, Moderna and CureVac.
Continue Reading The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)
Shortly after we posted about Moderna, Inc.’s October 2020 pledge not to enforce its COVID-19-related patents during the pandemic, the
Continue Reading The mRNA Patent and Competitive Landscape Through One Year of the COVID-19 Pandemic–Part I
It is advantageous for emerging companies to highlight their patent portfolio when seeking to attract investment, forge strategic partnerships, enter
Continue Reading How to Reduce Fees and Speed Time to Allowance at the US Patent & Trademark Office
AstraZeneca, the British-Swedish multinational pharmaceutical company currently collaborating with the University of Oxford on a COVID-19 vaccine, will purchase Alexion
Continue Reading As its COVID-19 Vaccine Nears Finalization, AstraZeneca Announces Deal to Buy Alexion for $39 Billion
In the fast-paced and dynamic environment of startup and emerging companies, standard operating procedures and compliance matters may often fall
Continue Reading Is it Time to Re-evaluate (or Create) Your Document Retention Policy?